International Journal of Head and Neck Surgery

Register      Login

VOLUME 8 , ISSUE 1 ( January-March, 2017 ) > List of Articles

RESEARCH ARTICLE

Transoral Laser Microsurgery vs Radiotherapy for Early Glottic Cancer: Study at Tertiary Care Center in India

Rajshekar Halkud, Purushottam Chavan, Ashok M Shenoy, Vikas Sharma, Namrata Ranganath, Tanvir Pasha, Poornima Shenoy, B Ravikumar, Suma M Narayana, Muhammed I Sharif, CR Vijay

Citation Information : Halkud R, Chavan P, Shenoy AM, Sharma V, Ranganath N, Pasha T, Shenoy P, Ravikumar B, Narayana SM, Sharif MI, Vijay C. Transoral Laser Microsurgery vs Radiotherapy for Early Glottic Cancer: Study at Tertiary Care Center in India. Int J Head Neck Surg 2017; 8 (1):15-20.

DOI: 10.5005/jp-journals-10001-1299

Published Online: 01-03-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

To compare laryngeal preservation rates, survival rates, and voice outcomes after treatment of early glottic cancer between transoral laser microsurgery (TLM) and radiotherapy (RT).

Materials and methods

A review of oncologic results was performed on a consecutive series of individuals with early-stage glottic carcinoma (T1 and T2) who were treated between 2011 and 2014 at Kidwai Memorial Institute of Oncology and had received either RT or TLM. Data were collected with a view to assess overall survival, disease-specific survival, laryngectomyfree survival, and laryngeal preservation rates. The Voice Handicap Index-30 (VHI-30) was used as the measure of voice quality after treatment.

Results

Two-year overall survival for TLM group was 93.8% and for RT group was 90.5%, p = 0.643. Disease-free survival (TLM = 90.6% vs RT = 76.2%) was not found to be significant (p-value = 0.104). Laryngeal preservation rate was 79.5% in TLM and 71.4% in RT group (p-value = 0.003). Laryngectomy- free survival was better in TLM (TLM = 96.9% vs RT = 76.2%, p = 0.003). Substage analysis showed equivalent voice for TLM (VHI = 6–12) and RT (VHI = 6–14) in T1a patients (p = 0.94), whereas voice outcome was better for RT in T1b (VHI = 10–16 for TLM vs VHI = 11–18 for RT, p = 0.044) and T2 (VHI = 21–29 for TLM vs VHI = 16–23 for RT, p = 0.002) stages.

Conclusion

Transoral laser microsurgery can be considered the treatment of choice for early glottic cancer in view of better laryngeal preservation rate and laryngectomy-free survival with added advantage of low treatment cost and shorter hospital stay compared with RT.

Clinical significance

Laryngeal cancers represent the most common malignancy of head and neck, with estimated worldwide incidence of 120,000 cases annually. Optimal treatment modality has generated significant controversy in literature. External beam RT, open partial laryngectomy, and TLM are various treatment options available. This study depicts TLM as a preferred modality for early glottic cancer.

How to cite this article

Shenoy AM, Sharma V, Chavan P, Halkud R, Ranganath N, Pasha T, Shenoy P, Ravikumar B, Narayana SM, Sharif MI, Vijay CR. Transoral Laser Microsurgery vs Radiotherapy for Early Glottic Cancer: Study at Tertiary Care Center in India. Int J Head Neck Surg 2017;8(1):15-20.


PDF Share
  1. Fractionation and glottic carcinoma. Int J Radiat Oncol Biol Phys 1997 Aug;39(1):1-2.
  2. Epidemiology. In: Gnepp DR, editor. Pathology of the head and neck. New York: Churchill Livingstone; 1988. p. 263-314.
  3. Management of T1-T2 glottic carcinomas. Cancer 2004 May;100(9):1786-1792.
  4. The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg 2007 Apr;15(2):82-88.
  5. Treatment of early-stage glottic cancer by transoral laser resection. Ann Otol Rhinol Laryngol 2007 Nov;116(11):832-836.
  6. Laser surgery in the larynx: early clinical experience with continuous CO2 laser. Ann Otol Rhinol Laryngol 1972 Dec;81(16):791-798.
  7. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2007 Oct;133(10):1044-1050.
  8. Voice quality after treatment for T1a glottic carcinoma radiotherapy versus laser cordectomy. Acta Oncol 2004 Jan;43(3):284-289.
  9. Adaptation and validation to the Spanish of the voice handicap index (VHI-30) and its shortened version (VHI-10). Acta Otorrinolaringol Esp 2007 Nov; 58(9):386-392.
  10. Development and standardization of voice handicap index (VHI) in the Indian language Kannada. Int J Appl Res 2016 Apr;2(5):248-250.
  11. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev 2002;(2):CD002027.
  12. Experimental laser retina hotocoagulation. J Opt Soc Am 1962;52:607.
  13. Results of curative laser microsurgery of laryngeal carcinomas. Am J Otolaryngol 1993 Mar-Apr;14(2):116-121.
  14. Transoral laser microsurgery for early glottic carcinoma. Surgery Curr Res 2014 Aug;4(5):201-205.
  15. Laser surgery of early glottic cancer in elderly. Acta Otorhinolaryngol Ital 2010 Aug;30(4):169-174.
  16. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg 2009 Dec;38(6):603-612.
  17. Comparative voice results after laser resection or irradiation of T1 vocal cord carcinoma. Arch Otolaryngol Head Neck Surg 1994 Sep;120(9):951-955.
  18. Voice results in patients with T1a glottic cancer treated by radiotherapy or endoscopic measures. Eur Arch Otorhinolaryngol 2002 Nov;259(10):547-550.
  19. Oncologic and voice outcomes after treatment of early glottic cancer: transoral laser microsurgery versus radiotherapy candace. J Otolaryngol Head Neck Surg 2012 Dec;41(6):381-388.
  20. Management of early-stage laryngeal cancer. Otolaryngol Clin North Am 2008 Aug;41(4):757-769.
  21. Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. Ann Oto Rhinol Laryngol 2006 Aug;115(8):581-586.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.